Toe the line or face the fine (5% of EU turnover)
This article was originally published in Scrip
Executive Summary
Legal experts are advising pharmaceutical companies to carefully review the recently amended EU Penalties Regulation, under which certain infringements of paediatric and pharmacovigilance laws for centrally authorised drugs can now lead to financial penalties of up to 5% of the marketing authorisation holder's annual EU turnover. The amended regulation came into force on 2 July.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.